Author

L. Dobbyn

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:CRISPR screen· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

B. Vogelstein· 3 shared C. Bettegowda· 3 shared K. W. Kinzler· 3 shared M. Popoli· 3 shared N. Papadopoulos· 3 shared A. L. Cook· 2 shared B. Ptak· 2 shared J. D. Cohen· 2 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

B. Vogelstein

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape

A. L. Cook, S. Sur, L. Dobbyn, E. Watson, J. D. Cohen, B. Ptak, B. S. Lee, S. Paul, E. Hsiue, M. Popoli, B. Vogelstein, N. Papadopoulos, C. Bettegowda, K. Gabrielson, S. Zhou, , N. Wyhs

A SMG1 inhibitor disrupts nonsense-mediated decay, increasing expression of neoantigens from truncating mutations and enhancing immune targetable peptides on cancer cells.

bioRxiv · Dec 28, 2023Cancer Biology

An Isogenic Cell Line Panel for Sequence-based Screening of Targeted Anti-cancer Drugs

A. L. Cook, N. Wyhs, S. B. Sur, B. Ptak, M. Popoli, L. Dobbyn, T. Papadopoulos, C. Bettegowda, N. Papadopoulos, B. Vogelstein, S. Zhou, K. W. Kinzler

The paper creates an isogenic cell line panel for drug screening, finding that most lines did not fully inactivate genes but a subset had biallelic disruptions, enabling drug response testing.

bioRxiv · Aug 6, 2021Cancer Biology

Assessing aneuploidy with repetitive element sequencing.

C. Douville, J. D. Cohen, J. Ptak, M. Popoli, J. Schaefer, N. Silliman, L. Dobbyn, R. E. Schoen, J. Tie, P. Gibbs, M. Goggins, C. L. Wolfgang, T.-L. Wang, I.-M. Shih, R. Karchin, , B. Vogelstein

The paper describes a PCR-based assay for detecting aneuploidy in low DNA samples, showing 49% prevalence in non-metastatic cancers and 80% sensitivity when combined with other biomarkers.

bioRxiv · Jun 5, 2019Cancer Biology